Lian Cui
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Lian Cui has a total of 95 co-authors. Here are the top co-authors by number of shared publications:
- Yuling Shi
Department of Dermatology, Shanghai Skin Disease Hospital, Tongji University School of Medicine, Shanghai, China
7 shared publications - Chunyuan Guo
Department of Dermatology, Shanghai Skin Disease Hospital, Tongji University School of Medicine, Shanghai, China
4 shared publications - Dawei Huang
Department of Dermatology, Shanghai Skin Disease Hospital, Tongji University School of Medicine, Shanghai, China
4 shared publications - Zeyu Chen
Department of Dermatology, Shanghai Skin Disease Hospital, Tongji University School of Medicine, Shanghai, People’s Republic of China
4 shared publications - Bingjie Li
Shanghai Institute of Nutrition and Health, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Shanghai, China
3 shared publications Hao Mei
Institute of Psoriasis, Tongji University School of Medicine, Shanghai, China
3 shared publications
Latest Publications
- Open Access
- 3 September 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1) , 9453
Author Correction: Double-stranded RNA and ROS scavenging nanoplatform for modulating skin inflammation
- 3 September 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1) , 9453
Open AccessAuthor Correction: Double-stranded RNA and ROS scavenging nanoplatform for modulating skin inflammation
- Open Access
- 1 September 2026
- Published by Taylor & Francis in Clinical, Cosmetic and Investigational Dermatology
- Vol. ume 19, 1-10
Complete Skin Clearance is Associated with HADS-Defined Absence of Anxiety and Depressive Symptoms After IL-17A Inhibitor Treatment in Moderate-to-Severe Psoriasis: Evidence from the SPEECH Cohort
Background: Psoriasis is a chronic immune-mediated disease associated with anxiety, depressive symptoms, and impaired quality of life, potentially involving interacting psychosocial and inflammatory pathways. During biologic treatment, psychological symptoms may improve alongside skin disease, but whether complete skin clearance (CSC) is associated with Hospital Anxiety and Depression Scale (HADS)-defined absence of anxiety and depressive symptoms remains unclear. Objective: To examine whether CSC, defined as PASI100, was associated with HADS-defined absence of anxiety and depressive symptoms after 12-week IL-17A inhibitor treatment in moderate-to-severe psoriasis. Methods: Patients receiving IL-17A inhibitors were identified from the Shanghai Psoriasis Effectiveness Evaluation CoHort (SPEECH). Eligible patients had complete baseline data, week-12 Psoriasis area and severity index (PASI) and HADS assessments. PASI responses represented percentage improvement from baseline and were categorized as PASI< 75, PASI75–< 100, or PASI100. The primary outcomes were week-12 HADS-A = 0 and HADS-D = 0, and the secondary outcomes were week-12 HADS-A and HADS-D as continuous outcomes. Logistic and linear regression, subgroup, and sensitivity analyses were performed. Results: Among 233 patients, 32 (13.7%) achieved PASI< 75, 99 (42.5%) PASI75–< 100, and 102 (43.8%) PASI100. Baseline HADS-A and HADS-D were comparable across groups. Compared with PASI100, PASI75–< 100 was associated with lower odds of HADS-A = 0 (adjusted OR [aOR], 0.40; 95% confidence interval [CI], 0.20– 0.78) and HADS-D = 0 (aOR, 0.48; 95% CI, 0.25– 0.95), and higher week-12 HADS-A (adjusted β, 1.10; 95% CI, 0.34– 1.86) and HADS-D (adjusted β, 0.95; 95% CI, 0.18– 1.72). For PASI< 75 versus PASI100, the corresponding aORs for HADS-A = 0 and HADS-D = 0 were 0.22 (95% CI, 0.08– 0.62) and 0.27 (95% CI, 0.09– 0.81), respectively. Subgroup and sensitivity analyses yielded consistent findings. Conclusion: CSC was associated with a higher likelihood of HADS-defined absence of anxiety and depressive symptoms in the treatment of moderate-to-severe psoriasis.
- 1 September 2026
- Published by Taylor & Francis in Clinical, Cosmetic and Investigational Dermatology
- Vol. ume 19, 1-10
Open AccessComplete Skin Clearance is Associated with HADS-Defined Absence of Anxiety and Depressive Symptoms After IL-17A Inhibitor Treatment in Moderate-to-Severe Psoriasis: Evidence from the SPEECH Cohort
Background: Psoriasis is a chronic immune-mediated disease associated with anxiety, depressive symptoms, and impaired quality of life, potentially involving interacting psychosocial and inflammatory pathways. During biologic treatment, psychological symptoms may improve alongside skin disease, but whether complete skin clearance (CSC) is associated with Hospital Anxiety and Depression Scale (HADS)-defined absence of anxiety and depressive symptoms remains unclear. Objective: To examine whether CSC, defined as PASI100, was associated with HADS-defined absence of anxiety and depressive symptoms after 12-week IL-17A inhibitor treatment in moderate-to-severe psoriasis. Methods: Patients receiving IL-17A inhibitors were identified from the Shanghai Psoriasis Effectiveness Evaluation CoHort (SPEECH). Eligible patients had complete baseline data, week-12 Psoriasis area and severity index (PASI) and HADS assessments. PASI responses represented percentage improvement from baseline and were categorized as PASI< 75, PASI75–< 100, or PASI100. The primary outcomes were week-12 HADS-A = 0 and HADS-D = 0, and the secondary outcomes were week-12 HADS-A and HADS-D as continuous outcomes. Logistic and linear regression, subgroup, and sensitivity analyses were performed. Results: Among 233 patients, 32 (13.7%) achieved PASI< 75, 99 (42.5%) PASI75–< 100, and 102 (43.8%) PASI100. Baseline HADS-A and HADS-D were comparable across groups. Compared with PASI100, PASI75–< 100 was associated with lower odds of HADS-A = 0 (adjusted OR [aOR], 0.40; 95% confidence interval [CI], 0.20– 0.78) and HADS-D = 0 (aOR, 0.48; 95% CI, 0.25– 0.95), and higher week-12 HADS-A (adjusted β, 1.10; 95% CI, 0.34– 1.86) and HADS-D (adjusted β, 0.95; 95% CI, 0.18– 1.72). For PASI< 75 versus PASI100, the corresponding aORs for HADS-A = 0 and HADS-D = 0 were 0.22 (95% CI, 0.08– 0.62) and 0.27 (95% CI, 0.09– 0.81), respectively. Subgroup and sensitivity analyses yielded consistent findings. Conclusion: CSC was associated with a higher likelihood of HADS-defined absence of anxiety and depressive symptoms in the treatment of moderate-to-severe psoriasis.
- Open Access
- 17 August 2026
- Published by Springer Nature in Nature Immunology
- Vol. 27 (10) , 2172
Author Correction: IL-17D-induced inhibition of DDX5 expression in keratinocytes amplifies IL-36R-mediated skin inflammation
- 17 August 2026
- Published by Springer Nature in Nature Immunology
- Vol. 27 (10) , 2172
Open AccessAuthor Correction: IL-17D-induced inhibition of DDX5 expression in keratinocytes amplifies IL-36R-mediated skin inflammation
- Open Access
- 13 May 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Double-stranded RNA and ROS scavenging nanoplatform for modulating skin inflammation
Double-stranded RNA (dsRNA) and reactive oxygen species (ROS) contribute to the exacerbation of skin inflammatory diseases such as psoriasis and atopic dermatitis. While antioxidant strategies have been extensively explored, approaches to neutralize pathogenic dsRNA remain limited. Here, we show that Mo90Ce10, a cerium-doped polyoxometalate, concurrently targets dsRNA and ROS to mitigate cutaneous inflammation. In vitro, Mo90Ce10 scavenges ROS and suppresses type I interferon responses by directly binding dsRNA through its oxygen-rich, hydrogen bond-forming surface. Its structural template, {Mo154}, exhibits weaker activity. In vivo, Mo90Ce10 reduces disease severity, dsRNA-induced inflammation, ROS burden, and neutrophil infiltration. Leveraging its negative charge and self-assembly properties, we further develop a transdermal platform by complexing Mo90Ce10 with the cationic peptide TD-1 and co-loading methotrexate, thereby enhancing drug penetration andtherapeutic efficacy while reducing recurrence. Together, these findings establish Mo90Ce10 as a multifunctional modulator of dsRNA- and ROS-driven inflammation and a promising transdermal delivery platform for inflammatory diseases.
- 13 May 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessDouble-stranded RNA and ROS scavenging nanoplatform for modulating skin inflammation
Double-stranded RNA (dsRNA) and reactive oxygen species (ROS) contribute to the exacerbation of skin inflammatory diseases such as psoriasis and atopic dermatitis. While antioxidant strategies have been extensively explored, approaches to neutralize pathogenic dsRNA remain limited. Here, we show that Mo90Ce10, a cerium-doped polyoxometalate, concurrently targets dsRNA and ROS to mitigate cutaneous inflammation. In vitro, Mo90Ce10 scavenges ROS and suppresses type I interferon responses by directly binding dsRNA through its oxygen-rich, hydrogen bond-forming surface. Its structural template, {Mo154}, exhibits weaker activity. In vivo, Mo90Ce10 reduces disease severity, dsRNA-induced inflammation, ROS burden, and neutrophil infiltration. Leveraging its negative charge and self-assembly properties, we further develop a transdermal platform by complexing Mo90Ce10 with the cationic peptide TD-1 and co-loading methotrexate, thereby enhancing drug penetration andtherapeutic efficacy while reducing recurrence. Together, these findings establish Mo90Ce10 as a multifunctional modulator of dsRNA- and ROS-driven inflammation and a promising transdermal delivery platform for inflammatory diseases.
- Open Access
- 1 January 2025
- Published by Wiley in Dermatologic Therapy
- Vol. 2025 (1)
Comprehensive Analysis of Effectiveness and Cost‐Effectiveness of Treatments for Psoriasis Integrating Clinician‐ and Patient‐Reported Outcomes: A Cohort Study From SPEECH
Effective and cost‐effective management strategies for psoriasis are crucial for clinical decision‐making. In the management of psoriasis, evidence concerning the effectiveness and cost‐effectiveness of therapies from both clinicians’ and patients’ perspectives is vital for clinical decision‐making. To compare the effectiveness and cost‐effectiveness of acitretin, methotrexate, phototherapy, and biologics (adalimumab, ustekinumab, guselkumab, secukinumab, and ixekizumab) in treating chronic plaque psoriasis, we collected the data from the Shanghai Psoriasis Effectiveness Evaluation CoHort (SPEECH), an observational, multicenter, and prospective registry. Integrating both clinician‐ and patient‐reported outcomes allows for a comprehensive evaluation of treatment impacts, capturing clinical disease improvements as well as patient‐perceived quality of life enhancements, thereby providing a more complete perspective compared to analyses focusing solely on clinical outcomes. Proportions of patients achieving 75% improvement in Psoriasis Area and Severity Index (PASI 75), PASI 90, PASI 100, minimally important difference in Dermatology Life Quality Index (DLQI MID), DLQI 0/1, and Patient Global Assessment (PtGA) MID at 12 weeks were evaluated. The number needed to treat (NNT) and incremental cost per responder (ICPR) were computed for treatments relative to acitretin. A total of 1916 patients with chronic plaque psoriasis were analyzed, with 240 patients on acitretin, 459 on methotrexate, 391 on phototherapy, 64 on adalimumab, 164 on ustekinumab, 97 on guselkumab, 298 on secukinumab, and 203 on ixekizumab. At 12 weeks, patients on methotrexate (adjusted relative risk [RR], 2.03 [95% CI, 1.66–2.48]), phototherapy (RR, 2.01 [95% CI, 1.64–2.46]), adalimumab (RR, 2.22 [95% CI, 1.66–2.96]), ustekinumab (RR, 2.86 [95% CI, 2.27–3.62]), guselkumab (RR, 3.34 [95% CI, 2.54–4.38]), secukinumab (RR, 3.38 [95% CI, 2.74–4.16]), and ixekizumab (RR, 3.59 [95% CI, 2.88–4.47]) were more likely to achieve PASI 75 versus patients on acitretin. Comparable rankings were observed for PASI 90, PASI 100, DLQI MID, DLQI 0/1, and PtGA MID. Additionally, methotrexate and phototherapy demonstrated numerically lower ICPR values compared to other evaluated treatments, while ixekizumab exhibited the lowest ICPR among the biologics. Overall, our study indicated that ixekizumab, secukinumab, guselkumab, and ustekinumab demonstrated superior effectiveness compared to other therapies at 12 weeks. Methotrexate and phototherapy offered the best cost‐effectiveness, while ixekizumab led in cost‐effectiveness among biologics.
- 1 January 2025
- Published by Wiley in Dermatologic Therapy
- Vol. 2025 (1)
Open AccessComprehensive Analysis of Effectiveness and Cost‐Effectiveness of Treatments for Psoriasis Integrating Clinician‐ and Patient‐Reported Outcomes: A Cohort Study From SPEECH
Effective and cost‐effective management strategies for psoriasis are crucial for clinical decision‐making. In the management of psoriasis, evidence concerning the effectiveness and cost‐effectiveness of therapies from both clinicians’ and patients’ perspectives is vital for clinical decision‐making. To compare the effectiveness and cost‐effectiveness of acitretin, methotrexate, phototherapy, and biologics (adalimumab, ustekinumab, guselkumab, secukinumab, and ixekizumab) in treating chronic plaque psoriasis, we collected the data from the Shanghai Psoriasis Effectiveness Evaluation CoHort (SPEECH), an observational, multicenter, and prospective registry. Integrating both clinician‐ and patient‐reported outcomes allows for a comprehensive evaluation of treatment impacts, capturing clinical disease improvements as well as patient‐perceived quality of life enhancements, thereby providing a more complete perspective compared to analyses focusing solely on clinical outcomes. Proportions of patients achieving 75% improvement in Psoriasis Area and Severity Index (PASI 75), PASI 90, PASI 100, minimally important difference in Dermatology Life Quality Index (DLQI MID), DLQI 0/1, and Patient Global Assessment (PtGA) MID at 12 weeks were evaluated. The number needed to treat (NNT) and incremental cost per responder (ICPR) were computed for treatments relative to acitretin. A total of 1916 patients with chronic plaque psoriasis were analyzed, with 240 patients on acitretin, 459 on methotrexate, 391 on phototherapy, 64 on adalimumab, 164 on ustekinumab, 97 on guselkumab, 298 on secukinumab, and 203 on ixekizumab. At 12 weeks, patients on methotrexate (adjusted relative risk [RR], 2.03 [95% CI, 1.66–2.48]), phototherapy (RR, 2.01 [95% CI, 1.64–2.46]), adalimumab (RR, 2.22 [95% CI, 1.66–2.96]), ustekinumab (RR, 2.86 [95% CI, 2.27–3.62]), guselkumab (RR, 3.34 [95% CI, 2.54–4.38]), secukinumab (RR, 3.38 [95% CI, 2.74–4.16]), and ixekizumab (RR, 3.59 [95% CI, 2.88–4.47]) were more likely to achieve PASI 75 versus patients on acitretin. Comparable rankings were observed for PASI 90, PASI 100, DLQI MID, DLQI 0/1, and PtGA MID. Additionally, methotrexate and phototherapy demonstrated numerically lower ICPR values compared to other evaluated treatments, while ixekizumab exhibited the lowest ICPR among the biologics. Overall, our study indicated that ixekizumab, secukinumab, guselkumab, and ustekinumab demonstrated superior effectiveness compared to other therapies at 12 weeks. Methotrexate and phototherapy offered the best cost‐effectiveness, while ixekizumab led in cost‐effectiveness among biologics.
- 4 October 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 10 (40) , eadp5332
N 6 -methyladenosine modification–tuned lipid metabolism controls skin immune homeostasis via regulating neutrophil chemotaxis
Disrupted N 6 -methyladenosine (m 6 A) modification modulates various inflammatory disorders. However, the role of m 6 A in regulating cutaneous inflammation remains elusive. Here, we reveal that the m 6 A and its methyltransferase METTL3 are down-regulated in keratinocytes in inflammatory skin diseases. Inducible deletion of Mettl3 in murine keratinocytes results in spontaneous skin inflammation and increases susceptibility to cutaneous inflammation with activation of neutrophil recruitment. Therapeutically, restoration of m 6 A alleviates the disease phenotypes in mice and suppresses inflammation in human biopsy specimens. We support a model in which m 6 A modification stabilizes the mRNA of the lipid-metabolizing enzyme ELOVL6 via the m 6 A reader IGF2BP3, leading to a rewiring of fatty acid metabolism with a reduction in palmitic acid accumulation and, consequently, suppressing neutrophil chemotaxis in cutaneous inflammation. Our findings highlight a previously unrecognized epithelial-intrinsic m 6 A modification–lipid metabolism pathway that is essential for maintaining epidermal and immune homeostasis and lay the basis for potential therapeutic targeting of m 6 A modulators to attenuate inflammatory skin diseases.
- 4 October 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 10 (40) , eadp5332
N 6 -methyladenosine modification–tuned lipid metabolism controls skin immune homeostasis via regulating neutrophil chemotaxis
Disrupted N 6 -methyladenosine (m 6 A) modification modulates various inflammatory disorders. However, the role of m 6 A in regulating cutaneous inflammation remains elusive. Here, we reveal that the m 6 A and its methyltransferase METTL3 are down-regulated in keratinocytes in inflammatory skin diseases. Inducible deletion of Mettl3 in murine keratinocytes results in spontaneous skin inflammation and increases susceptibility to cutaneous inflammation with activation of neutrophil recruitment. Therapeutically, restoration of m 6 A alleviates the disease phenotypes in mice and suppresses inflammation in human biopsy specimens. We support a model in which m 6 A modification stabilizes the mRNA of the lipid-metabolizing enzyme ELOVL6 via the m 6 A reader IGF2BP3, leading to a rewiring of fatty acid metabolism with a reduction in palmitic acid accumulation and, consequently, suppressing neutrophil chemotaxis in cutaneous inflammation. Our findings highlight a previously unrecognized epithelial-intrinsic m 6 A modification–lipid metabolism pathway that is essential for maintaining epidermal and immune homeostasis and lay the basis for potential therapeutic targeting of m 6 A modulators to attenuate inflammatory skin diseases.
- Open Access
- 1 January 2023
- Published by Wiley in Dermatologic Therapy
- Vol. 2023 (1)
The Clinical Significance of the Derived Neutrophil‐to‐Lymphocyte Ratio in Differentiating Occult Psoriatic Arthritis from Psoriasis Alone
Background. Occult psoriatic arthritis (PsA) refers to a subset of psoriasis patients showing lesions on imaging but do not exhibit arthritis symptoms. Objective. This study was aimed to discover a simple biomarker that could be easily incorporated in clinical practice to identify occult PsA patients, defined as psoriasis patients with lesions on imaging but without arthritis symptoms, among silent psoriasis (PsO) patients, defined as psoriasis patients without any arthritis symptoms. Methods. A total of 149 silent PsO patients, including 83 PsO alone patients, defined as psoriasis patients without any arthritis symptoms and evidence of lesions on imaging, and 66 occult PsA patients, were enrolled in this cross‐sectional study, and they all underwent blood tests to determine hematological inflammation biomarkers. Results. Occult PsA patients had a higher derived neutrophil‐to‐lymphocyte ratio (dNLR) (1.6 (1.3–2.2) vs. 1.3 (0.9–1.8), p < 0.001), body mass index (BMI) (25.2 (23.7–28.1) vs. 24.0 (21.9–26.0), p = 0.002), diabetes mellitus (DM) rate (30.3% vs. 7.2%, p < 0.001), and nail involvement rate (65.2% vs. 41.0%, p = 0.003) than patients with PsO alone. A prediction nomogram was established, and the area under the curve (AUC) was 0.843. The sensitivity and specificity of the model for identifying occult PsA patients were 77.3% and 81.9%, respectively. Conclusion. Our findings suggest that dNLR is a valuable diagnostic biomarker for occult PsA, and our prediction nomogram could provide clinicians with a useful tool for differentiating occult PsA patients from PsO alone patients.
- 1 January 2023
- Published by Wiley in Dermatologic Therapy
- Vol. 2023 (1)
Open AccessThe Clinical Significance of the Derived Neutrophil‐to‐Lymphocyte Ratio in Differentiating Occult Psoriatic Arthritis from Psoriasis Alone
Background. Occult psoriatic arthritis (PsA) refers to a subset of psoriasis patients showing lesions on imaging but do not exhibit arthritis symptoms. Objective. This study was aimed to discover a simple biomarker that could be easily incorporated in clinical practice to identify occult PsA patients, defined as psoriasis patients with lesions on imaging but without arthritis symptoms, among silent psoriasis (PsO) patients, defined as psoriasis patients without any arthritis symptoms. Methods. A total of 149 silent PsO patients, including 83 PsO alone patients, defined as psoriasis patients without any arthritis symptoms and evidence of lesions on imaging, and 66 occult PsA patients, were enrolled in this cross‐sectional study, and they all underwent blood tests to determine hematological inflammation biomarkers. Results. Occult PsA patients had a higher derived neutrophil‐to‐lymphocyte ratio (dNLR) (1.6 (1.3–2.2) vs. 1.3 (0.9–1.8), p < 0.001), body mass index (BMI) (25.2 (23.7–28.1) vs. 24.0 (21.9–26.0), p = 0.002), diabetes mellitus (DM) rate (30.3% vs. 7.2%, p < 0.001), and nail involvement rate (65.2% vs. 41.0%, p = 0.003) than patients with PsO alone. A prediction nomogram was established, and the area under the curve (AUC) was 0.843. The sensitivity and specificity of the model for identifying occult PsA patients were 77.3% and 81.9%, respectively. Conclusion. Our findings suggest that dNLR is a valuable diagnostic biomarker for occult PsA, and our prediction nomogram could provide clinicians with a useful tool for differentiating occult PsA patients from PsO alone patients.
- Top Cited PapersOpen Access
- 21 October 2022
- Published by Springer Nature in Nature Immunology
- Vol. 23 (11) , 1577-1587
IL-17D-induced inhibition of DDX5 expression in keratinocytes amplifies IL-36R-mediated skin inflammation
Aberrant RNA splicing in keratinocytes drives inflammatory skin disorders. In the present study, we found that the RNA helicase DDX5 was downregulated in keratinocytes from the inflammatory skin lesions in patients with atopic dermatitis and psoriasis, and that mice with keratinocyte-specific deletion of Ddx5 (Ddx5∆KC) were more susceptible to cutaneous inflammation. Inhibition of DDX5 expression in keratinocytes was induced by the cytokine interleukin (IL)-17D through activation of the CD93–p38 MAPK–AKT–SMAD2/3 signaling pathway and led to pre-messenger RNA splicing events that favored the production of membrane-bound, intact IL-36 receptor (IL-36R) at the expense of soluble IL-36R (sIL-36R) and to the selective amplification of IL-36R-mediated inflammatory responses and cutaneous inflammation. Restoration of sIL-36R in Ddx5∆KC mice with experimental atopic dermatitis or psoriasis suppressed skin inflammation and alleviated the disease phenotypes. These findings indicate that IL-17D modulation of DDX5 expression controls inflammation in keratinocytes during inflammatory skin diseases.
- 21 October 2022
- Published by Springer Nature in Nature Immunology
- Vol. 23 (11) , 1577-1587
Top Cited PapersOpen AccessIL-17D-induced inhibition of DDX5 expression in keratinocytes amplifies IL-36R-mediated skin inflammation
Aberrant RNA splicing in keratinocytes drives inflammatory skin disorders. In the present study, we found that the RNA helicase DDX5 was downregulated in keratinocytes from the inflammatory skin lesions in patients with atopic dermatitis and psoriasis, and that mice with keratinocyte-specific deletion of Ddx5 (Ddx5∆KC) were more susceptible to cutaneous inflammation. Inhibition of DDX5 expression in keratinocytes was induced by the cytokine interleukin (IL)-17D through activation of the CD93–p38 MAPK–AKT–SMAD2/3 signaling pathway and led to pre-messenger RNA splicing events that favored the production of membrane-bound, intact IL-36 receptor (IL-36R) at the expense of soluble IL-36R (sIL-36R) and to the selective amplification of IL-36R-mediated inflammatory responses and cutaneous inflammation. Restoration of sIL-36R in Ddx5∆KC mice with experimental atopic dermatitis or psoriasis suppressed skin inflammation and alleviated the disease phenotypes. These findings indicate that IL-17D modulation of DDX5 expression controls inflammation in keratinocytes during inflammatory skin diseases.
- 15 March 2022
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 142 (9) , 2343-2352
IL-17A Promotes Psoriasis-Associated Keratinocyte Proliferation through ACT1-Dependent Activation of YAP–AREG Axis
- 15 March 2022
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 142 (9) , 2343-2352
IL-17A Promotes Psoriasis-Associated Keratinocyte Proliferation through ACT1-Dependent Activation of YAP–AREG Axis